IKZF1/3
ACTIVE_COMPETITORS 1 Asset
CLINICAL_EXPERIMENTS 3 Live Trials
BIOCLASS THERAPEUTIC_AREA
[01_MECHANISTIC_DESCRIPTIVE_NARRATIVE]
The ion zinc finger protein degrader
[02_MACROMOLECULAR_3D_CONFORMATION]
Interactive structural projection resolved from the AlphaFold database engine configuration dataset mapping.
IKZF1/3
UNIPROT: Q13422
ALPHAFOLD_3D_PREDICTION
INITIALIZING_STRUCTURAL_BIOMATRIX...
[03_ACTIVE_COMPETITIVE_LANDSCAPE]
THERAPEUTIC ASSET
ALIAS
MAX PHASE
SPONSORING ISSUER / CORPORATION
[04_CROSS_REFERENCED_CLINICAL_EXPERIMENTS]
REGISTRY ID
EXPERIMENT TITLE
STAGE
EVALUATED ASSET
STATUS
NCT07284758 ↗
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
P-2
CFT7455
recruiting
NCT07280013 ↗
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
P-1
CFT7455
recruiting
NCT04756726 ↗
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
P-1
CFT7455
active not recruiting